Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab - PubMed
3 hours ago
- #Metastatic Disease
- #Immunotherapy
- #Hepatocellular Carcinoma
- The study examines the prognostic impact of intrahepatic tumor burden in patients with hepatocellular carcinoma (HCC) and extrahepatic metastases treated with atezolizumab plus bevacizumab.
- A multicenter retrospective analysis of 306 patients showed that intrahepatic tumor burden and macrovascular invasion significantly affected overall survival, with median OS varying by severity groups.
- Multivariate analysis identified intrahepatic tumor burden as an independent predictor of survival, while extrahepatic metastatic sites were not significantly associated with prognosis.
- Conclusions suggest that intrahepatic tumor burden is crucial for risk stratification and treatment optimization in metastatic HCC under this therapy.